Latest Precision Medicine News

Page 3 of 5
Telix Pharmaceuticals secures Transitional Pass-Through payment status for its next-generation prostate cancer imaging agent Gozellix, paving the way for broader US patient access and streamlined provider reimbursement.
Ada Torres
Ada Torres
23 Sept 2025
Proteomics International Laboratories has achieved ISO 15189 certification for its Australian lab, marking a pivotal step in commercialising its precision diagnostic tests like PromarkerD and PromarkerEso.
Ada Torres
Ada Torres
18 Sept 2025
Proteomics International Laboratories announces the planned retirement of its founder and Managing Director, Dr Richard Lipscombe, in February 2026, marking a pivotal leadership transition as the company seeks a new CEO to drive its next growth phase.
Ada Torres
Ada Torres
9 Sept 2025
Proteomics International has unveiled new clinical data confirming its PromarkerEso blood test can accurately detect early stages of esophageal adenocarcinoma, potentially transforming screening for a cancer with poor prognosis.
Ada Torres
Ada Torres
8 Sept 2025
PYC Therapeutics has completed dosing in its Phase 1 study of PYC-001 for Autosomal Dominant Optic Atrophy, showing strong safety and early signs of improved vision. The company plans to launch a global Phase 1/2 trial later this year.
Ada Torres
Ada Torres
5 Sept 2025
PYC Therapeutics has reported promising safety data from the initial phase of its clinical trial for PYC-003, an RNA therapy targeting the root cause of Polycystic Kidney Disease. The findings, presented at the ANZSN conference, highlight the drug’s tolerability in healthy volunteers, paving the way for further clinical development.
Ada Torres
Ada Torres
29 Aug 2025
PYC Therapeutics reported a 14.5% rise in income to AUD 26.17 million for FY2025 alongside a 33.3% increase in net loss, while increasing its stake in Vision Pharma to 97.1%. The auditor flagged material uncertainty over the company’s ability to continue as a going concern.
Ada Torres
Ada Torres
28 Aug 2025
Rhythm Biosciences has formalised a strategic co-marketing partnership with the Know Your Lemons Foundation to promote its geneType Breast Cancer Risk Assessment Test, expanding access to early detection tools for women in the US and Australia.
Ada Torres
Ada Torres
28 Aug 2025
Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.
Ada Torres
Ada Torres
21 Aug 2025
Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.
Ada Torres
Ada Torres
21 Aug 2025
PYC Therapeutics has escalated dosing to the highest level in its Phase 1a trial of PYC-003 and begun dosing patients with Polycystic Kidney Disease, marking key progress toward regulatory milestones.
Ada Torres
Ada Torres
8 Aug 2025
Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.
Ada Torres
Ada Torres
6 Aug 2025